Assessment of doxorubicin delivery devices based on tailored bare polycaprolactone against glioblastoma
Niza E, Castro-Osma JA, Posadas I, Alonso-Moreno C, Bravo I, Garzón A, Canales-Vázquez J, Ceña V, Lara-Sánchez A, Albaladejo J, Otero A.
Pharm. 2019 Mar 10;558:110-119. Epub 2019 Jan 9. PMID: 30639216. doi: 10.1016/j.ijpharm.2018.12.079.